<DOC>
	<DOCNO>NCT00833859</DOCNO>
	<brief_summary>The purpose study find program intensive chemotherapy gemcitabine , docetaxel capecitabine follow advanced form focus radiation aim patient 's tumor follow chemotherapy increase chance patient 's pancreatic tumor remove completely .</brief_summary>
	<brief_title>Neoadjuvant Gemcitabine , Docetaxel , Capecitabine Combination With Stereotactic Radiosurgery</brief_title>
	<detailed_description>- Cycle 1 2 : - Days 4 , 11 25 , 32 ... .gemcitabine 750 mg/m^2 intravenous piggy back ( IVPB ) 30 min - Days 4 , 11 25 , 32 ... .docetaxel 30 mg/m^2 IVPB 1 hour - Days 1-14 22-35 ... .capecitabine 750 mg/m^2 oral twice daily - Each cycle 21 day long - SRS : Day 43 ... .25 Gy single fraction pancreatic tumor gross target volume - Cycle 3 4 : - Days 54 , 61 75 , 82 ... .gemcitabine 750 mg/m^2 IVPB 30 min - Days 54 , 61 75 , 82 ... .docetaxel 30 mg/m^2 IVPB 1 hour - Days 51-64 ... .capecitabine 750 mg/m^2 oral twice daily - Each cycle 21 day long - Surgery : Exploratory laparotomy laparoscopy follow pancreaticoduodenectomy central pancreatectomy without vein resection reconstruction appropriate .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients must histologically cytologically confirm pancreatic adenocarcinoma borderline resectable disease . Borderline resectable lesion define : circumferential tumor abutment superior mesenteric vein ( SMV ) portal vein ( PV ) SMV/PV confluence &lt; 180o . circumferential tumor abutment superior mesenteric artery ( SMA ) &lt; 180o . Short segment encasement ( 360o ) PV SMV amenable partial vein resection reconstruction . encasement gastroduodenal artery origin hepatic artery Patients must measurable disease . No previous chemotherapy radiation pancreas . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 ( Karnofsky &gt; 60 % . Patients must normal organ marrow function define : leukocyte &gt; 3,000/μL absolute neutrophil count &gt; 1,000/μL platelet &gt; 100,000/μL creatinine within normal institutional limit OR creatinine clearance &gt; 60 mL/min/1.73 m2 patient creatinine level institutional normal total bilirubin &lt; institutional upper limit normal ( ULN ) . Patients may biliary stent drain low total bilirubin range . Aspartate Aminotransferase ( AST ) serum glutamic oxaloacetic transaminase ( SGOT ) / alanine aminotransferase ( ALT ) serum glutamic pyruvic transaminase ( SGPT ) AST ALT may 2.5 time ULN alkaline phosphatase &lt; ULN ; alkaline phosphatase may 4 time ULN AST ALT &lt; ULN . Has negative serum urine pregnancy test within 7 day prior initiation therapy ( female patient childbearing potential ) . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Patients agree continue contraception 30 day date last study drug administration . Ability understand willingness sign write informed consent document . Patients metastatic disease ineligible . Patients prior chemotherapy pancreatic adenocarcinoma . Patients receive prior radiation abdominal site eligible . Prior malignancy last 3 year , except basal cell carcinoma , squamous cell insitu cervical cancer . Patients peripheral neuropathy &gt; grade 2 . Patients history severe hypersensitivity reaction Taxotere ( docetaxel ) , drug formulate polysorbate 80 , gemcitabine , capecitabine . Patients may receive investigational agent . ECOG PS 34 Pregnant woman exclude study gemcitabine , capecitabine , docetaxel Class D agents potential teratogenic abortifacient effect . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement creatinine clearance &lt; 30 ml/min ( CockcroftGault method ) . Patients must comorbid inflammatory condition bowel Crohn 's Disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>stereotactic radiosurgery</keyword>
	<keyword>borderline resectable pancreatic cancer</keyword>
	<keyword>gastrointestinal</keyword>
	<keyword>pancreas</keyword>
</DOC>